共 42 条
- [41] Real-World Comparative Outcomes of First-Line (1L) Venetoclax plus Obinutuzumab (VenO) Versus Covalent Bruton's Tyrosine Kinase Inhibitors (BTKis) ± Anti-CD20 Therapy Among Patients With Chronic Lymphocytic Leukemia (CLL) in the United States (US) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S355 - S355
- [42] Author's Response to: Comment on "Impact of EML4-ALK Variants and Co- Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion- Positive NSCLC: Real-World Outcomes From the GuardantINFORM Database" and "Critical Evaluation of Methodological Approaches in ALK TKI Research: Addressing Confounding Factors and Statistical Robustness" JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (11) : e66 - e67